"Royalty Pharma is excited to partner with AstraZeneca®, one of the world's leading pharmaceutical companies, in this groundbreaking royalty transaction. We believe that Royalty Pharma is in a unique position to collaborate with companies such as AstraZeneca® to assist in optimizing the value of their strategic initiatives. We look forward to continuing to be the preeminent partner to leading research institutions, hospitals, universities and biopharmaceutical companies. We are also pleased to expand the reach of our existing royalty portfolio, which includes leading oncology and antiviral products to include HUMIRA®, the fastest growing anti-TNF therapy."

Pablo Legorreta, Chief Executive Officer, Royalty Pharma

HUMIRA® is used in adults to reduce the signs and symptoms of moderate to severe rheumatoid arthritis, like joint pain and swelling. It may also help prevent further damage to your bones and joints, and improve your ability to perform daily activities. HUMIRA® is a prescription medication taken by injection. It can be used alone or with methotrexate or with certain other medications. Rheumatoid Arthritis (RA) is an autoimmune disease that has been linked to a protein produced in the body called TNF (tumor necrosis factor) that can cause inflammation. People with RA have too much TNF in the affected areas of the body. HUMIRA® works by binding TNF and helps block the process that can lead to the pain, inflammation and progression of joint damage that RA can cause. Because TNF blockers - including HUMIRA® - affect the immune system, they can lower the ability to fight infections and may cause other serious side effects.

Therapeutic Area

Rheumatoid Arthritis
Psoriatic Arthritis
Juvenile Rheumatoid Arthritis
Anti-TNF (gastrointestinal) Crohn's Disease

Acquisition Date

Oct 2006